The antiemetic drug trimethobenzamide prevents hypophagia due to acetyl salicylate, but not to 5-HT1B or 5-HT1C agonists.
Pretreatment with the antiemetic agent trimethobenzamide (TMB) prevented the hypophagic response of rats to acetyl salicylate (a known emetic in man and dogs). However, it did not affect the hypophagic responses to the 5-HT1B agonist RU24969, or to the 5-HT1C/5-HT1B agonists mCPP and TFMPP. The results therefore suggest that the hypophagic effects of the 5-HT agonists do not involve a malaise-dependent mechanism similar to that mediating the effect of acetyl salicylate.
Kennett
G A
GA
Institute of Neurology, Queen Square, London, UK.
Curzon
G
G
D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D001241:Aspirin / Q000037:antagonists & inhibitors*; D001549:Benzamides / Q000494:pharmacology*; D005247:Feeding Behavior / Q000187:drug effects*; D005508:Food Deprivation; D007211:Indoles / Q000494:pharmacology; D008297:Male; D010879:Piperazines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000502:physiology*
D000932:Antiemetics; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; C018406:1-(3-trifluoromethylphenyl)piperazine; C025145:5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1H indole; D012701:Serotonin; D001241:Aspirin; C015068:1-(3-chlorophenyl)piperazine; C100146:trimethobenzamide